therapy, food intake was gradually increased for one to two weeks. When fasting therapy and adoptive immune therapy" were used in combination, adoptive immune therapy followed the termination of fasting therapy by two or three days.

3. Assay of Cyclic Nucleotides: 16 Serum cyclic AMP and cyclic GMP were assayed by radioimmunoassay using a kit (Yamasa Shoyu Co. Ltd, Japan).

4. Measurement of Immune Activity: Peripheral blood lymphocytes were obtained from heparinized blood by centrifugation on a lymphocyte separation medium, Ficoll (Pharmazia Fine Chemicals AB, Sweden), and Conray (Daiichi Seiyaku, Tokyo), respectively.
     a. T-cell number. The T-cell number was determined by rosette formation with sheep erythrocytes.
     b. Stimulation index (SI). To determine the rate of blastogenesis of lymphocytes by phytohemagglutinin (PHA), after adding PHA to isolated lymphocytes, the value of the ratio of 3 H-thymidine incorporation into PHA-treated cells to the control without PHA was calculated.
     c. Natural Killer (NK) cytotoxity. Lymphocytes at a concentration of 5 x 106/ml were prepared in RPMI 1640 supplemented with 10% fetal calf serum. As target cells, K562 were used. A 0.1 ml lymphocyte suspension was poured into a 96-well microtitre plate,51 Cr labeled target cells were added, and the amount of 51 Cr released after incubation of effector cells for 4 hours at 37° was measured

5. Adoptive Immune (Sensitized Lymphocyte) Therapy:
     a. Selection of healthy donors. We chose healthy donors who were considered to have normal immune activity, fulfilling the following criteria

1. White blood cells: 6,000 to 8,000 cells/ mm.3
2. PPD: at least above 10 x 10 mm.
3. CCM (Cancer check of the related meridian)'°: below 6 points.
4. Immunosuppressive acidic protein (IAP): below the concentration of IAP 450 ug/dl.

b. Lymphocyte preparation. Peripheral blood (100 ml) was drawn from the selected healthy donors. According to the method of Tsuji,17 lymphocytes were prepared by centrifugation on lymphyocyte separation medium (Lymphoprep, Nyegaard & Co., A.S., Oslo, Norway). An approximately 1-2 x 108 lymphocyte suspension in 100 ml of physiological saline sultion was aseptically infused into the recipient via intravenous drip.
     c. Treatment As subjects, 17 advanced and progressive cancer patients with decreased cellular immune activity were treated (Table 1). According to the method of tumor marker release induction into the blood previously described, retinol palmitate (vitamin A, 100,000 IU, Eisai Co., Tokyo) was administered by intramuscular injection.18 Hyperthermia treatment was carried out 1 to 3 hours later in a far infrared sauna box (56° C, 20 min) inducing effective release of cancer antigens into the blood After hyperthermia treatment, between the 24th and 30th hour a lymphocyte suspension prepared from healthy donors was infused by intravenous drip.

Results

1. Improvement in Ryodoraku Charts by Fasting Therapy.
Fig. 1. shows the Ryodoraku chart of a patient with progressive breast cancer prior to fasting therapy, and Fig. 2 shows that of the same patient after the fasting therapy. The electric currency of the meridians has improved. In particular, the differences between the left and right sides of the same meridian have decreased and the CCM has improved.

2. Improvement in Serum Level of Cyclic Nucleotides by Fasting Therapy (Fig. 3).
Normal levels of serum cyclic AMP and cyclic GMP were taKen as 30 pmotes/ ml and 2-5 pmoles/ml, respectively. The serum levels of cyclic AMP and cyclic GMP of the breast cancer patient quickly normalized as compared to the serum levels prior to commencement of the fasting therapy (Fig. 3).

3. Possibility of Cancer Antigen Release Being Caused by Fasting Therapy. The same level of Elastase-1, the tumor